Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$3.13 USD
-0.12 (-3.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.50 +0.37 (11.82%) 6:42 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELDN 3.13 -0.12(-3.69%)
Will ELDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELDN
Best Momentum Stocks to Buy for July 14th
New Strong Buy Stocks for July 14th
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Other News for ELDN
Catalyst Watch: Palantir earnings, Firefly Aerospace IPO, OPEC+, and the Fed's SLOOS report
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase ...
12 Health Care Stocks Moving In Monday's After-Market Session
Eledon Pharmaceuticals (ELDN) Gains Positive Outlook Amidst New Developments | ELDN Stock News
Craig-Hallum bullish on Eledon Pharmaceuticals, initiates with a Buy